Budget impact analysis of the use of paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease

Valentina Lorenzoni, Giuseppe Turchetti

DOI: https://doi.org/10.7175/fe.v15i3.938

Abstract

OBJECTIVE: Evaluation of the budget impact of the use of paricalcitol (compared to alternative treatment) for secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) when used at two different timing of therapy.
METHODS: Two Markov models related to a different timing of treatment have been developed: the intermediate stage of chronic kidney disease (CKD3) and the dialysis stage. The analysis was conducted with the perspective of the Italian National Health System and over a 5-year time horizon. The clinical and economic data used in the model were derived from the literature and other assumptions were made based on the opinion of clinical experts. Univariate sensitivity analysis was conducted to test the robustness of the results.
RESULTS: The base case shows that starting paricalcitol treatment from the dialysis stage (considering 13,311 possible candidates) is associated with a reduction in direct costs from € 1,782,921,351 to € 1,622,357,209 over 5 years. Furthermore, considering a collective of 1,000 subjects eligible and starting treatment with paricalcitol since the intermediate stages of the CKD, is associated with an overall cost saving of € 1,197,500.
DISCUSSION AND CONCLUSIONS: Paricalcitol is expected to be cost-saving in patients with SHPT in Italy considering both the therapeutic indications of the drug. Moreover, despite the higher cost of using paricalcitol in pre-dialysis stage, an early treatment of SHPT determine an overall decrease in direct medical costs.

Keywords

Budget impact analysis; Paracalcitol; Secondary hyperparathyroidism; Chronic kidney disease

Full Text:

HTML PDF

References

  • Centre for Disease Control and Prevention (USA). Prevalence of Chronic Disease and Associated Risk Factors – United States. Disponibile on line all’indirizzo: http://cdc.gov./mmwr/preview/mmwrhtml/mm5608a2.htm
  • Braun L, VipanSood, Hogue S, et al. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis 2012; 5: 151-63
  • Garofalo C, Liberti MA, Sagliocca A, et al. Epidemiologia e prognosi della malattia renale cronica in Italia. G Ital Nefrol 2012; 29(S58): S3-S11
  • Cicchetti A, Ruggeri M, Codella P, et al. I costi socio-sanitari dell’insufficienza renale cronica. Farmacoeconomia e percorsi terapeutici 2011; 12: 21-8
  • Smith DH, Gullion CM, Nichols G, et al. Cost f medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004; 15: 1300-6; http://dx.doi.org/10.1097/01.ASN.0000125670.64996.BB
  • Lee A, Belozerff V, Song X, et al. Cost of treatment and clinical events for secondary hyperparathyroidism. Am J Pharm Benefits 2013; 5: 24-35
  • Cozzolino M, Olivi L, Voli E, et al. Prevenzione e trattamento dell’iperparatiroidismo secondario nel paziente con malattia renale cronica allo stadio 3-5 non in dialisi. G Ital Nefrol 2009; 26: S30-S35
  • Ong LM, Narayanan P, Goh HK, et al. Oral Paricalcitol in ESRD Study Group.Randomized controlled trial to compare the efficacy and safety of oral paricalcitol with oral calcitriol in dialysis patients with secondary hyperparathyroidism. Nephrology (Carlton) 2013; 18: 194-200; http://dx.doi.org/10.1111/nep.12029
  • Kettler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27: 3270-8; http://dx.doi.org/10.1093/ndt/gfs018
  • Han T, Gong R, Quan D, et al. Meta-analysis: the efficacy and safety of paracalcitol for the treatment of secondary hyperparathyroidism and proteinuria in chronic kidney disease. Biomed Res Int. 2013; 2013: 320560; http://dx.doi.org/10.1155/2013/320560
  • Mazzaferro S, Brancaccio D, Messa P, et al. Management of secondary hyperparathyroidism in Italy: results of the Italian FARO survey. J Nephrol 2011; 24: 225-35; http://dx.doi.org/10.5301/JN.2010.6193
  • Sharma A, Kettler M, Marshall TS, et al. Comparative cost analysis of managemnet of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients. J Med Econ 2013; 16: 1129-36; http://dx.doi.org/10.3111/13696998.2013.823092
  • Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney diesease. Kidney Int 2005; 68: 2823-8; http://dx.doi.org/10.1111/j.1523-1755.2005.00755.x
  • Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647-52; http://dx.doi.org/10.1053/j.ajkd.2009.04.036
  • Coyne DW, Andress DL, Amdahl MJ, et al. Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study. Nephrol Dial Transplant 2013; 28: 2260-8; http://dx.doi.org/10.1093/ndt/gft227
  • De Nicola L, Conte G, Russo D, et al. Antiproteinuric effect of add-on paricalcitol in CKD patients under maximal tolerated inhibition of renin-angiotensin system a prospective observational study. BMC Nephrol 2012; 20: 150; http://dx.doi.org/10.1186/1471-2369-13-150
  • de Lorenzo A, Salanova L, Bomback AS, et al. Oral paricalcitol as antiproteinuric agent in chronic kidney disease. Nephrologia 2013; 33: 709-15
  • Mascia S, Garofalo C, Donnarumma G, et al. Ruolo del paracalcitolo nella terapia conservativa della malattia renale cronica: stato dell’arte e… unmet needs. Giornale Italiano di Nefrologia 2010; 27: 616-28
  • Lee GH, Benner D, Regidor DL, et al. Impact of kidney bone disease and its management on survival of patients on dialysis. J Ren Nutr 2007; 17: 38-44; http://dx.doi.org/10.1053/j.jrn.2006.07.006
  • KDIGO 2012 Clinical Practice Guideline for the Evaluation and management of Chronic Kidney Disease. Kidney International Supplements 2013; 3: 128-33
  • Nuijten M, Andress DL, Marx SE, et al. Cost Effectiveness of Paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Investig 2010; 30: 545-57; http://dx.doi.org/10.2165/11536310-000000000-00000
  • The EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, et al. Effects cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482-94; http://dx.doi.org/10.1056/NEJMoa1205624
  • Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003; 349(5): 446-56.
  • Registro Italiano Dialisi e Trapianto. Disponibile on line all’indirizzo: http://www.sin-italy.org
  • 2012 Annual Report of the Dialysis Outcomes and Practice Patterns Study: Hemodialysis Data 1997-2011. Arbor Research Collaborative for Health, Ann Arbor, MI. Disponibile on line all’indirizzo: http://www.dopps.org/annualreport/
  • Scalone L, Borghetti F, Brunori G, et al. Cost-benefit analysis of supplemented very low-protein diet versus dialysis in elderly CKD5 patients. Nephrol Dial Transplant 2010; 25: 907-13; http://dx.doi.org/10.1093/ndt/gfp572
  • Tariffario delle prestazioni di assistenza specialistica ambulatoriale. Supplemento ordinario n.8 alla Gazzetta Ufficiale Serie Generale n.23 del 28-1-2013
  • Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant 2004; 19: 1174-81; http://dx.doi.org/10.1093/ndt/gfh123
  • Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCI on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800; http://dx.doi.org/10.1111/j.1523-1755.2005.00596.x
  • Rapporto annuale sull’attività di ricovero ospedaliero. Dati SDO 2011. Ministero della Salute, 2012
  • Il valore del trapianto. Un’analisi empirica dei consumi sanitari e dei costi dei trapiantati di reni in Italia. Censis 2013
  • Indici storici di inflazione per anno in l’Italia. Disponibile on line all’indirizzo: http://www.inflation.eu/inflation-rates/italy/historic-inflation/cpi-inflation-italy.aspx
  • Turchetti G, Scalone L, Della Casa Alberighi O, et al. The rationale of pharmacoeconomic analysis in rheumatologic indications. Clin Expl Rheumatol 2012; 30: S64-S71
  • Turchetti G, Spadoni E, Geisler E. Health technology assessment. Evaluation of biomedical innovative technologies. IEEE Eng Med and Biol Mag 2010; 29: 70-6; http://dx.doi.org/10.1109/MEMB.2010.936553

Refbacks

  • There are currently no refbacks.




© SEEd srl